|
|
|
|
|
|
Market Potential: On behalf of a financial investor, Health Advances created a five-year risk-adjusted global
revenue forecast for a blockbuster oncology drug. The team conducted in-depth interviews with opinion leaders in the US and
Europe to understand the drug’s potential across multiple indications and treatment settings.
Business Strategy: Health Advances worked with a major medical device company to conduct an in-depth analysis
of the oncology ablation market to inform the client’s strategic options going forward. The project outputs included a market
sizing analysis with detailed segmentation in both the US and EU, and an in-depth evaluation of current and emerging
technologies.
Pricing Strategy: As a novel cancer agent was completing Phase III studies targeted at three cancers: colon, lung and breast, Health Advances conducted a detailed analysis leading to the recommended launch price taking into consideration the potential product positioning in current and future indications.
Clinical Trial Planning: Health Advances worked with a non-profit disease foundation to identify ways to streamline and enhance the outcomes of clinical trials in multiple myeloma. The team analyzed over 100 ongoing and proposed multiple myeloma trials and spoke with leaders in industry, academia, and the FDA to identify best practices.
Business Development: Health Advances worked with the business development team at a specialty pharmaceutical company to identify and analyze potential acquisition targets to supplement the company’s early-stage pipeline. The team developed a rigorous set of acquisition criteria and used them to identify attractive assets and prioritize therapeutic markets for entry.
Due Diligence: Health Advances was asked to perform strategic due diligence for a large pharmaceutical company looking to grow its oncology franchise through the acquisition of a novel therapeutic cancer vaccine. Health Advances conducted a detailed analysis of the market to predict the competitive position of the therapy, understand the logistical issues surrounding commercialization, and conducted a study of pricing and reimbursement to inform the financial forecast.
Competitive Positioning: The Competitive Intelligence group of a large biotech client asked Health Advances to analyze how three competitive programs in development for hormone refractory prostate cancer would impact the competitive positioning of the client’s molecule. The team developed detailed profiles on each drug, including current clinical trial status, previous results, likely positioning, and expected resources dedicated to further development and marketing.
Commercialization Strategy: Health Advances provided a full commercialization strategy for a device for intraoperative margin assessment in breast cancer lumpectomies. The team assessed the potential market by segment and the likely reimbursement for the technology, and recommended clinical, pricing, and sales strategies.
Follow-on Biologics: Health Advances developed a systemic approach to address the emergence of follow-on biologics in oncology. By assessing a combination of product, indication, and market factors, we projected the differential impact of follow-on biologics across products and patient segments.
|
|
 |
|
|
|
|
